Immunotherapy

Immunotherapy has been studied in 103 papers since 2017: 2 trials and 19 observational studies in people, 3 in animals, 2 in cells, 60 reviews; 44 in the past year. The newest story, Oct 25, 2026: “Dietary restriction enhances melanoma immunotherapy in mice”.

Intervention

103 papers study it18 findingsUpdated

MeSH

Research on it is growing 16% faster than aging research as a whole: 211 papers in the latest year counted

8 new papers in 30 daysSee all 103 papers on immunotherapy

At a glance

The findings reach people, from one lab or study. 7 independent labs in 3 countries; 147 trials, none about aging, 25 with no results posted.

“In multivariable analysis, IT was associated with a lower hazard of SPC (HR, 0.57; 95% CI, 0.41-0.79; P < 0.001).”
The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance ActivationClinical cancer research : an official journal of the American Association for Cancer Research2026doi:10.1158/1078-0432.ccr-25-3886

None of its findings points the other way.

Mice and humans: a single group. Cells and worms or flies: nothing yet.
  • 7 independent labs in 3 countries
  • 147 trials, none about aging, 25 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 3 of 147 trials sponsored by its developers
  • Human trial2
  • Humans19
  • Animals3
  • Cells2
  • In silico16

What did studies of immunotherapy find?

9

Studies of immunotherapy measured 9 outcomes, among them cellular senescence, senescence phenotypes and senescent cells.

Cellular senescence

downin reviews2

2 studies
  1. Immunotherapy decreases cellular senescence.

    Review

  2. Immunotherapy decreases cellular senescence.

    Review

More on Cellular senescence

Senescence phenotypes

downin animal1

1 study
  1. Immunotherapy decreases senescence phenotypes in animal.

    Review

Senescent cells

downin animal1

1 study
  1. Immunotherapy decreases senescent cells in animal.

    Review

More on Senescent cells

Insulin resistance

downin reviews1

1 study
  1. Immunotherapy decreases insulin resistance.

    Review

Tumor control

upin humans1

1 study
  1. Immunotherapy improves tumor control in humans (liver cancer).

    Reviewliver cancerliver

Olfactory perception

downin humans1

1 study
  1. Immunotherapy is linked with worse olfactory perception in humans following immunotherapy.

    Humansfollowing immunotherapy

Mortality

downin humans1

1 study
  1. Immunotherapy decreases mortality in humans (melanoma) (almost -30%).

    Reviewmelanoma

clearance of protein aggregates

upin reviews1

1 study
  1. Immunotherapy increases clearance of protein aggregates.

    Review

Inflammation

downin reviews1

1 study
  1. Immunotherapy decreases inflammation (by neutralizing extracellular protein aggregates).

    Reviewby neutralizing extracellular protein aggregates

More on Inflammation

What is immunotherapy linked with?

7

Studies link immunotherapy with 7 measures, among them cellular senescence, second primary cancers and frailty.

Cellular senescence

mixedin reviews1

1 study
  1. Immunotherapy is associated with cellular senescence.

    Review

More on Cellular senescence

Second primary cancers

downin humans1HR 0.57

1 study
  1. Immunotherapy is linked with a lower risk of second primary cancers in humans (HR 0.57, 95% CI 0.41-0.79, P < 0.001).

    Humansmedian follow-up of 47.5 monthsn = 5,576

More on Second primary cancers

Frailty

mixedin humans1

1 study
  1. Immunotherapy is associated with frailty in humans during six treatment cycles (p = 0.037).

    Humansduring six treatment cyclesn = 205

LUAD-CSRS

mixedin silico1

1 study
  1. LUAD-CSRS predicts immunotherapy in silico (lung adenocarcinoma).

    In silicolung adenocarcinoma

More on LUAD-CSRS

Risk score

upin humans1

1 study
  1. Risk score is associated with immunotherapy in patients with high risk scores.

    Humansin patients with high risk scores

More on Risk score

Cellular senescence-related risk score signature

upin humans1

1 study
  1. Cellular senescence-related risk score signature predicts immunotherapy in humans (colon cancer).

    Humanscolon cancer

More on Cellular senescence-related risk score signature

Senescore

upin humans1

1 study
  1. Senescore predicts immunotherapy in humans (gastric cancer).

    Humansgastric cancer

More on Senescore

What acts on immunotherapy?

1

Studies name cellular senescence as acting on immunotherapy.

Cellular senescence

downin humans1

1 study
  1. Cellular senescence impairs immunotherapy in humans (malignant lung tumors).

    Reviewmalignant lung tumors

More on Cellular senescence

Has immunotherapy been tested in people?

0 of 147 about aging

Yes: 2 trials and 19 observational studies in people have been published, and 147 trials are registered.

Latest change Breast neoplasm: Early phase 1 → Phase 1/2Nov 13, 2026

In trials

40 of 83

Stopped

  • NCT00089856TerminatedNeoplasm metastasis

    Based on futility analysis showing \<30% chance of meeting primary endpoint.

  • NCT04653389TerminatedHepatocellular carcinoma

    The treatment efficacy was not satisfactory.

  • NCT06199882SuspendedBiliary tract carcinoma

    Patient recruitment difficulties

  • NCT03634800TerminatedMultiple myeloma

    Lack of patient accruals.

  • NCT04558684SuspendedRectal neoplasms

    Inadequate patient enrollment

  • NCT03116529TerminatedSarcoma

    Limited Accrual

Who is developing immunotherapy?

1 company: Brooklyn ImmunoTherapeutics.

Companies
  • Brooklyn ImmunoTherapeuticsPhase 2squamous cell carcinoma of the oral cavity

Trial sponsors

Funding

37 grants since 2016

National Institute on Aging$14.3MNational Cancer Institute$8.6MJapan Society for the Promotion of Science¥73.8M

Latest

Dec 2025: 4Jan 2026: 5Feb 2026: 8Mar 2026: 4Apr 2026: 2May 2026: 4Jun 2026: 1Jul 2026: 2Aug 2026: 4Sep 2026: 0Oct 2026: 4Nov 2026: 442 papers in 12 months
Biochimica et Biophysica Acta Molecular Basis of Disease

Lung cancer outcomes linked to senescence in blood vessel cells

An observational analysis linked senescence in blood-vessel-lining cells to better immunotherapy responses and longer survival in people with non-small cell lung cancer.An observational analysis linked senescence in blood-vessel-lining cells to better immunotherapy responses and longer survival in people with non-small cell lung cancer.

Study in peopleCellular senescence
Genome Medicine

Dietary restriction enhances melanoma immunotherapy in mice

Experiments in mouse melanoma models found that dietary restriction suppressed tumor growth through effects that depended on the immune system.Experiments in mouse melanoma models found that dietary restriction suppressed tumor growth through effects that depended on the immune system.

See all 103 papers on immunotherapy